-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Guangzhou Poinsettia Pharmaceuticals entered the administrative approval stage with the valsartan oral solution that was produced by imitating Class 3 products, and it is expected to become the first valsartan oral solution product in China
.
Valsartan is a commonly used antihypertensive drug in clinical practice.
In 2020, the total terminal sales of Chinese public medical institutions and Chinese urban physical pharmacies will exceed 5 billion yuan
.
.
Valsartan is a commonly used antihypertensive drug in clinical practice.
In 2020, the total terminal sales of Chinese public medical institutions and Chinese urban physical pharmacies will exceed 5 billion yuan
.
Valsartan is one of the most widely used antihypertensive drugs in the domestic market
.
The original manufacturer of this product is Novartis, which was approved for marketing in the United States in July 2001.
It is mainly used for the treatment of mild to moderate essential hypertension
.
.
The original manufacturer of this product is Novartis, which was approved for marketing in the United States in July 2001.
It is mainly used for the treatment of mild to moderate essential hypertension
.
According to data from Minet.
com, in 2020, the total sales of valsartan in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 5 billion yuan
.
com, in 2020, the total sales of valsartan in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 5 billion yuan
.
Affected by the epidemic and centralized procurement, the terminal sales of valsartan in China's public medical institutions fell by 10.
47% in 2020, while the terminal sales of physical pharmacies in Chinese cities did not drop but rose, and remained at the level of 1 billion yuan
.
The latest data shows that the terminal sales of valsartan in Chinese urban brick-and-mortar pharmacies are expected to increase by 3.
57% in 2021
.
47% in 2020, while the terminal sales of physical pharmacies in Chinese cities did not drop but rose, and remained at the level of 1 billion yuan
.
The latest data shows that the terminal sales of valsartan in Chinese urban brick-and-mortar pharmacies are expected to increase by 3.
57% in 2021
.
Sales of terminal valsartan in physical pharmacies in Chinese cities (unit: 10,000 yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
In 2020, among the TOP5 generic names of drugs that act on the renin-angiotensin system in Chinese urban physical pharmacies, sartans are on the screen, and valsartan ranks first, the only variety with sales exceeding 1 billion yuan; Irbe Sartan and Telmisartan ranked second and third respectively, and it was still difficult to catch up with valsartan for a while
.
Valsartan and amlodipine is the only compound antihypertensive drug on the list, and its sales in brick-and-mortar pharmacies have continued to rise in recent years
.
.
Valsartan and amlodipine is the only compound antihypertensive drug on the list, and its sales in brick-and-mortar pharmacies have continued to rise in recent years
.
Generic name TOP5 of drugs acting on the renin-angiotensin system (unit: 100 million yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
At present, valsartan products that have been marketed in China include tablets, dispersible tablets and capsules, and no company for oral liquids has yet been approved for marketing
.
Changzhou No.
4 Medicine and Guangzhou Yipinhong Pharmaceutical have successively submitted 3 types of marketing applications for generic valsartan oral solution.
Changzhou No.
4 Medicine has completed the review of the product, but it has not been approved
.
.
Changzhou No.
4 Medicine and Guangzhou Yipinhong Pharmaceutical have successively submitted 3 types of marketing applications for generic valsartan oral solution.
Changzhou No.
4 Medicine has completed the review of the product, but it has not been approved
.
The registration status of Guangzhou Poinsettia Pharmaceuticals has been changed to "under approval".
If it is successfully approved, it will be regarded as over-evaluation, and it will become the first valsartan oral solution product in China
.
If it is successfully approved, it will be regarded as over-evaluation, and it will become the first valsartan oral solution product in China
.
Data source: Minet database, NMPA
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 urban physical pharmacies in cities and above (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 urban physical pharmacies in cities and above (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
Recently, Guangzhou Poinsettia Pharmaceuticals entered the administrative approval stage with the valsartan oral solution that was produced by imitating Class 3 products, and it is expected to become the first valsartan oral solution product in China
.
Valsartan is a commonly used antihypertensive drug in clinical practice.
In 2020, the total terminal sales of Chinese public medical institutions and Chinese urban physical pharmacies will exceed 5 billion yuan
.
.
Valsartan is a commonly used antihypertensive drug in clinical practice.
In 2020, the total terminal sales of Chinese public medical institutions and Chinese urban physical pharmacies will exceed 5 billion yuan
.
Valsartan is one of the most widely used antihypertensive drugs in the domestic market
.
The original manufacturer of this product is Novartis, which was approved for marketing in the United States in July 2001.
It is mainly used for the treatment of mild to moderate essential hypertension
.
.
The original manufacturer of this product is Novartis, which was approved for marketing in the United States in July 2001.
It is mainly used for the treatment of mild to moderate essential hypertension
.
According to data from Minet.
com, in 2020, the total sales of valsartan in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 5 billion yuan
.
com, in 2020, the total sales of valsartan in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 5 billion yuan
.
Affected by the epidemic and centralized procurement, the terminal sales of valsartan in China's public medical institutions fell by 10.
47% in 2020, while the terminal sales of physical pharmacies in Chinese cities did not drop but rose, and remained at the level of 1 billion yuan
.
The latest data shows that the terminal sales of valsartan in Chinese urban brick-and-mortar pharmacies are expected to increase by 3.
57% in 2021
.
47% in 2020, while the terminal sales of physical pharmacies in Chinese cities did not drop but rose, and remained at the level of 1 billion yuan
.
The latest data shows that the terminal sales of valsartan in Chinese urban brick-and-mortar pharmacies are expected to increase by 3.
57% in 2021
.
Sales of terminal valsartan in physical pharmacies in Chinese cities (unit: 10,000 yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
In 2020, among the TOP5 generic names of drugs that act on the renin-angiotensin system in Chinese urban physical pharmacies, sartans are on the screen, and valsartan ranks first, the only variety with sales exceeding 1 billion yuan; Irbe Sartan and Telmisartan ranked second and third respectively, and it was still difficult to catch up with valsartan for a while
.
Valsartan and amlodipine is the only compound antihypertensive drug on the list, and its sales in brick-and-mortar pharmacies have continued to rise in recent years
.
.
Valsartan and amlodipine is the only compound antihypertensive drug on the list, and its sales in brick-and-mortar pharmacies have continued to rise in recent years
.
Generic name TOP5 of drugs acting on the renin-angiotensin system (unit: 100 million yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
At present, valsartan products that have been marketed in China include tablets, dispersible tablets and capsules, and no company for oral liquids has yet been approved for marketing
.
Changzhou No.
4 Medicine and Guangzhou Yipinhong Pharmaceutical have successively submitted 3 types of marketing applications for generic valsartan oral solution.
Changzhou No.
4 Medicine has completed the review of the product, but it has not been approved
.
.
Changzhou No.
4 Medicine and Guangzhou Yipinhong Pharmaceutical have successively submitted 3 types of marketing applications for generic valsartan oral solution.
Changzhou No.
4 Medicine has completed the review of the product, but it has not been approved
.
The registration status of Guangzhou Poinsettia Pharmaceuticals has been changed to "under approval".
If it is successfully approved, it will be regarded as over-evaluation, and it will become the first valsartan oral solution product in China
.
If it is successfully approved, it will be regarded as over-evaluation, and it will become the first valsartan oral solution product in China
.
Data source: Minet database, NMPA
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 urban physical pharmacies in cities and above (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 urban physical pharmacies in cities and above (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
Recently, Guangzhou Poinsettia Pharmaceuticals entered the administrative approval stage with the valsartan oral solution that was produced by imitating Class 3 products, and it is expected to become the first valsartan oral solution product in China
.
Valsartan is a commonly used antihypertensive drug in clinical practice.
In 2020, the total terminal sales of Chinese public medical institutions and Chinese urban physical pharmacies will exceed 5 billion yuan
.
.
Valsartan is a commonly used antihypertensive drug in clinical practice.
In 2020, the total terminal sales of Chinese public medical institutions and Chinese urban physical pharmacies will exceed 5 billion yuan
.
Valsartan is one of the most widely used antihypertensive drugs in the domestic market
.
The original manufacturer of this product is Novartis, which was approved for marketing in the United States in July 2001.
It is mainly used for the treatment of mild to moderate essential hypertension
.
medicines medicines medicines high blood pressure high blood pressure.
The original manufacturer of this product is Novartis, which was approved for marketing in the United States in July 2001.
It is mainly used for the treatment of mild to moderate essential hypertension
.
According to data from Minet.
com, in 2020, the total sales of valsartan in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 5 billion yuan
.
Hospital Hospital Hospital Pharmacy Pharmacy Pharmacycom, in 2020, the total sales of valsartan in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 5 billion yuan
.
Affected by the epidemic and centralized procurement, the terminal sales of valsartan in China's public medical institutions fell by 10.
47% in 2020, while the terminal sales of physical pharmacies in Chinese cities did not drop but rose, and remained at the level of 1 billion yuan
.
The latest data shows that the terminal sales of valsartan in Chinese urban brick-and-mortar pharmacies are expected to increase by 3.
57% in 2021
.
47% in 2020, while the terminal sales of physical pharmacies in Chinese cities did not drop but rose, and remained at the level of 1 billion yuan
.
The latest data shows that the terminal sales of valsartan in Chinese urban brick-and-mortar pharmacies are expected to increase by 3.
57% in 2021
.
Sales of terminal valsartan in physical pharmacies in Chinese cities (unit: 10,000 yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
In 2020, among the TOP5 generic names of drugs that act on the renin-angiotensin system in Chinese urban physical pharmacies, sartans are on the screen, and valsartan ranks first, the only variety with sales exceeding 1 billion yuan; Irbe Sartan and Telmisartan ranked second and third respectively, and it was still difficult to catch up with valsartan for a while
.
Valsartan and amlodipine is the only compound antihypertensive drug on the list, and its sales in brick-and-mortar pharmacies have continued to rise in recent years
.
.
Valsartan and amlodipine is the only compound antihypertensive drug on the list, and its sales in brick-and-mortar pharmacies have continued to rise in recent years
.
Generic name TOP5 of drugs acting on the renin-angiotensin system (unit: 100 million yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
At present, valsartan products that have been marketed in China include tablets, dispersible tablets and capsules, and no company for oral liquids has yet been approved for marketing
.
Changzhou No.
4 Medicine and Guangzhou Yipinhong Pharmaceutical have successively submitted 3 types of marketing applications for generic valsartan oral solution.
Changzhou No.
4 Medicine has completed the review of the product, but it has not been approved
.
enterprise enterprise enterprise.
Changzhou No.
4 Medicine and Guangzhou Yipinhong Pharmaceutical have successively submitted 3 types of marketing applications for generic valsartan oral solution.
Changzhou No.
4 Medicine has completed the review of the product, but it has not been approved
.
The registration status of Guangzhou Poinsettia Pharmaceuticals has been changed to "under approval".
If it is successfully approved, it will be regarded as over-evaluation, and it will become the first valsartan oral solution product in China
.
If it is successfully approved, it will be regarded as over-evaluation, and it will become the first valsartan oral solution product in China
.
Data source: Minet database, NMPA
Note: Minet.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 urban physical pharmacies in cities and above (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 urban physical pharmacies in cities and above (excluding county and rural physical pharmacies) and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product in the terminal
.
